Cure8 research brief
Why This Matters
The work helps explain why smoking increases Crohn’s risk but seems protective for ulcerative colitis by identifying genetic loci and smoking-dependent gene expression changes that differ between the two diseases. That could inform future research into personalized prevention.
Who Should Pay Attention
Researchers in IBD genetics and gene–environment interactions; clinicians following advances in IBD risk science; patients interested in genetics and lifestyle risk factors
Study Snapshot
What To Know
The authors performed genome-wide interaction analyses in two cohorts and combined those results with mucosal eQTL data from IBD intestinal tissue. They report hundreds of candidate genetic variants showing multiplicative interactions with smoking and dozens of smoking-dependent cis-eQTLs in affected intestine.
Several loci showed opposite interaction patterns for CD compared with UC, and HLA residues were highlighted as associated with smoking status. The paper is presented as an abstract-level summary of a journal article (EBioMedicine).
The findings are hypothesis-generating: they nominate loci and smoking-dependent gene expression links rather than reporting clinical tests or interventions. These results may guide future mechanistic studies or eventually contribute to genotype-informed prevention strategies, but they do not by themselves change clinical care.
Keep In Mind
This entry is based on the article abstract (EBioMedicine). The results are genome-wide interaction and eQTL findings that are hypothesis-generating and require replication and further functional validation before clinical use.
Source Details
Review the original publication for the complete reporting, methods, and context.
Conflict statement: Declaration of interests R.K.W. received unrestricted research grants from Takeda, Johnson & Johnson, Tramedico, and Ferring, and received speaker’s fees from MSD, AbbVie, and Janssen. K.N.F. received a grant from Janssen Pharmaceuticals. G.D. received a grant from Royal DSM, advisory board fee from Pharmacosmos and AstraZeneca, and speakers fee from Abbvie. The remaining authors declared no potential conflict of interests.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.